Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

IFNgamma-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

ABSTRACT: CAR-T (Chimeric antigen receptor T cell) therapy has led to significant improvements in patient survival. However, a subset of patients experience high-grade toxicities, including cytokine release syndrome (CRS) and immune cell-associated hematological toxicity (ICAHT). We utilized IL-2Ralpha knockout mice to model toxicities with elevated levels of IL-6, IFNgamma, and TNFalpha and increased M1-like macrophages. Onset of CRS was accompanied by a reduction in peripheral blood neutrophils due to disruption of bone marrow neutrophil homeostasis characterized by an increase in apoptotic neutrophils and a decrease in proliferative and mature neutrophils. Both non-tumor-bearing and Emu-ALL tumor-bearing mice recapitulated the co-occurrence of CRS and neutropenia. IFNgamma-blockade alleviated CRS and neutropenia without affecting CAR-T efficacy. Mechanistically, a Th1-Th17 imbalance was observed to drive co-occurrence of CRS and neutropenia in an IFNgamma-dependent manner leading to decreased IL-17A and G-CSF, neutrophil production, and neutrophil survival. In patients, we observed an increase in the IFNgamma-to-IL-17A ratio in the peripheral blood during high-grade CRS and neutropenia. We have uncovered a biological basis for ICAHT and provide support for the use of IFNgamma-blockade to reduce both CRS and neutropenia.

ORGANISM(S): Mus musculus

PROVIDER: GSE308219 | GEO | 2025/09/17

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel treatment in lymphoma

Project description:Chimeric antigen receptor T cells have transformed the treatment of multiple hematologic malignancies, but are limited in application due to treatment-related toxicities. Cytokine release syndrome (CRS) and neurotoxicity (NT) are the primary toxicities associated with these therapies and are thought to be mediated by broad immune activation due to robust T-cell expansion. Current treatment of these toxicities utilize anti-IL-6 directed therapy and/or systemic glucocorticoids to mitigate the consequences of this complex inflammatory cascade. We sought to use anakinra, an IL-1R antagonist, as a prophylactic strategy to prevent clinically meaningful CRS/NT, defined as grade 2 or higher toxicity necessitating clinical intervention. Although our study, in line with others, demonstrated that IL-1R antagonism is insufficient to prevent such toxicities entirely, we were able to gain insight into the molecular immune signaling associated with breakthrough CRS & NT in the presence of anakinra prophylaxis using our scRNA dataset of patients treated with and without IL-1R antagonism. We demonstrate that IL-4 and IL-10 anti-inflammatory pathways in infused CAR-T products of both anakinra and non-anakinra cohorts were negatively associated with grade 2+ toxicities. We also found that expression of IFNg pathways and ligand-receptor activities, as well as cytokine levels of IFNg and CXCL10 in CD14+ monocytes, were significantly enriched in patients with breakthrough toxicity in the anakinra cohort. This correlated with an increase in IFNg in the peripheral blood of patients with breakthrough toxicities, among other cytokines. These data identify IFNg as a potential key mechanism in the development of CAR-T cell-associated toxcities and suggest that this pathway is also targetable and not inhibited by anakinra alone.

2025-05-14 | GSE246490 | GEO

Transcriptome analysis of neutrophils from recurrent vulvovaginal candidiasis patients and IL-17A-treated healthy controls

Project description:Recurrent vulvovaginal candidiasis (RVVC) is a common mucosal infectious disease characterized by recurrent episodes of vulvovaginal inflammation caused by Candida albicans. Neutrophils are critical innate immune cells in antifungal defense, and IL-17A plays an important regulatory role in neutrophil function. To explore the mechanism by which IL-17A regulates neutrophils in RVVC, we collected vaginal lavage fluid from 3 healthy women and 3 RVVC patients, isolated neutrophils, and treated healthy neutrophils with IL-17A. Total RNA was extracted from three groups (healthy control group A, healthy+IL-17A group B, and RVVC patient group C), followed by transcriptome sequencing. Through quality control, library construction, sequencing, alignment, gene expression quantification, and differential expression analysis, we aim to identify differentially expressed genes and key pathways related to RVVC pathogenesis and IL-17A regulation of neutrophils.

2026-06-12 | GSE335122 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a unifying predictive biomarker for both toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-05 | PXD076370 | Pride

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy

2026-09-05 | PXD076368 | Pride

IFNgamma-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

Project description:IFNgamma-driven skewing towards Th1 over Th17 differentiation underlies CRS and neutropenia in CAR-T therapy

| PRJNA1329248 | ENA

Transcriptome analysis of CD16/CD62L neutrophil subsets during human experimental endotoxemia

Project description:During systemic inflammation, different neutrophil subsets are mobilized to the blood circulation. These neutrophil subsets can be distinguished from normal circulating neutrophils (CD16bright/CD62Lbright) based on either an immature CD16dim/CD62Lbright or a CD16bright/CD62Ldim phenotype. Interestingly, the latter neutrophil subset is known to suppress lymphocyte proliferation ex vivo, but the underlying mechanism is largely unknown. We performed transcriptome analysis on the different neutrophil subsets to identify changes that are relevant for their functions. Neutrophil subsets were isolated by FACS sorting from the blood of healthy volunteers who were administered a single dose of lipopolysaccharide (LPS). The transcriptome was determined by microarray. The mobilized neutrophil subsets were characterized by specific transcriptome profiles reflecting their phase in neutrophil lifespan. Interestingly, the CD16bright/CD62Ldim suppressive neutrophils showed an interferon-induced transcriptome profile. This was confirmed by stimulation of peripheral neutrophils with IFNgamma. These cells acquired the capacity to suppress lymphocyte proliferation through the expression of programmed death ligand 1 (PD-L1). These data demonstrate that the suppressive phenotype of the neutrophil subset is induced by IFNgamma. Specific stimulation of neutrophils might have a pivotal role in regulating lymphocyte-mediated inflammation and autoimmune disease. After LPS infusion, blood was taken at t=0 and t=4 hours. Neutrophils were FACS sorted based on CD16 and CD62L expression. Gene expression of neutrophil subsets was assessed relative to t=0 as control.

2013-05-01 | E-GEOD-42358 | biostudies-arrayexpress

CAR T Cell Sytotoxic Supernatant Stimulates Monocytes to Drive Cytokine Storm

Project description:Chimeric antigen receptor (CAR) T cell-therapy is substantially constrained by cytokine release syndrome (CRS). The precise mechanisms underlying CAR T cell-therapy-associated CRS remain elusive. Here, we show that CAR T cell-induced tumor cytotoxicity activates monocytes to release IL-1β, IL-6, and TNF-α, key inflammatory cytokines driving CRS, via monocyte contact-independent manner.

2025-07-20 | GSE302543 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Patient_sample_RNAseq]

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a biomarker for high-grade toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-02 | GSE307358 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [TLR2_knockdown_monocyte_RNAseq]

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a biomarker for high-grade toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-02 | GSE307357 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Human_monocyte_RNAseq]

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a biomarker for high-grade toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-02 | GSE307356 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data